CEACAM5 and neoplasm: As for DFS evaluation, N2 tumor indicated poorer DFS (median 54-N0 vs 23-N1 vs 12-N2 months, P = 0.004), and tumor stage (median 12 months in stage III), pemetrexed–platinum based chemotherapy (median 21 months) and serum CEA positive were also significantly with worse DFS (median 48-positive vs 13-negtive months), with P = 0.002, P = 0.025, P = 0.014, respectively (Figure 1).